Literature DB >> 12592351

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin.

C M Zwaan, D Reinhardt, H Jürgens, D R Huismans, K Hählen, O P Smith, A Biondi, E R van Wering, J Feingold, G J L Kaspers.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12592351     DOI： 10.1038/sj.leu.2402749

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

Review 1.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

Review 2.  Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.

Authors:  Joseph Wynne; David Wright; Wendy Stock
Journal:  Blood Adv       Date:  2019-01-08

3.  A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study).

Authors:  Erica Brivio; Franco Locatelli; Marta Lopez-Yurda; Andrea Malone; Cristina Díaz-de-Heredia; Bella Bielorai; Claudia Rossig; Vincent H J van der Velden; Anneke C J Ammerlaan; Adriana Thano; Inge M van der Sluis; Monique L den Boer; Ying Chen; Barbara Sleight; Benoit Brethon; Karsten Nysom; Lucie Sramkova; Ingrid Øra; Luciana Vinti; Christiane Chen-Santel; Christian Michel Zwaan
Journal:  Blood       Date:  2021-03-25       Impact factor: 22.113

Review 4.  Application of immunotherapy in pediatric leukemia.

Authors:  Alan S Wayne
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

Review 5.  Antibody Based Therapies in Acute Leukemia.

Authors:  Nirali N Shah
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

6.  Combination of chemotherapy and gemtuzumab ozogamicin in adult Philadelphia positive acute lymphoblastic leukemia patient harboring CD33 expression.

Authors:  Patrice Chevallier; Beatrice Mahe; Richard Garand; Pascaline Talmant; Jean-Luc Harousseau; Jacques Delaunay
Journal:  Int J Hematol       Date:  2008-08-01       Impact factor: 2.490

Review 7.  Immunotherapy of childhood cancer: from biologic understanding to clinical application.

Authors:  Alan S Wayne; Christian M Capitini; Crystal L Mackall
Journal:  Curr Opin Pediatr       Date:  2010-02       Impact factor: 2.856

Review 8.  Immune-based therapeutics for pediatric cancer.

Authors:  Christian M Capitini; Crystal L Mackall; Alan S Wayne
Journal:  Expert Opin Biol Ther       Date:  2010-02       Impact factor: 4.388

Review 9.  Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.

Authors:  Keith J August; Aru Narendran; Kathleen A Neville
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546

10.  Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.

Authors:  Erin M Guest; Richard Aplenc; Lillian Sung; Susana C Raimondi; Betsy A Hirsch; Todd A Alonzo; Robert B Gerbing; Yi-Cheng Jim Wang; Samir B Kahwash; Amy Heerema-McKenney; Soheil Meshinchi; Alan S Gamis
Journal:  Blood       Date:  2017-07-03       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.